Dyadic to Present at H.C. Wainwright 23rd Annual Global Investment Conference
September 10, 2021 08:30 ET
|
Dyadic International, Inc.
JUPITER, Fla., Sept. 10, 2021 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further...
Dyadic and Sorrento Announce Binding Term Sheet to License Dyadic’s Lead COVID-19 Vaccine Candidate “DYAI-100” and C1 Technology for Protein-Based Coronavirus Vaccines and Therapeutics
August 11, 2021 08:35 ET
|
Dyadic International, Inc.
Sorrento to obtain exclusive rights in North and South America, Europe, major Asian countries (including Greater China and Japan) and certain other countries to utilize Dyadic’s C1 technology for the...
Dyadic Announces Technology Transfer and Licensing Agreement With South Africa’s Rubic Consortium Aiming to Develop and Commercialize Vaccines for Distribution Throughout the African Continent
July 27, 2021 08:20 ET
|
Dyadic International, Inc.
Arrangement includes C1 COVID-19 vaccine technology transfer and licensing agreementProvides potential funding pathway for a C1 manufactured COVID-19 vaccine to progress through Phase II and Phase III...
Dyadic’s C1 Production Platform Utilized in ZAPI Study Published in “VACCINES” a Leading Peer-Reviewed Scientific Journal
June 28, 2021 08:30 ET
|
Dyadic International, Inc.
Dyadic’s C1-cell protein production platform selected as a fast response vaccine manufacturing model against zoonotic diseases.C1 -cell platform expressed SBV antigen exhibited efficacy, potency, and...
Dyadic announces development of COVID-19 Vaccine in India
May 26, 2021 08:30 ET
|
Dyadic International, Inc.
JUPITER, Fla., May 26, 2021 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI) a global biotechnology company focused on further improving, applying and...
Dyadic to Present at Upcoming Events
May 03, 2021 08:30 ET
|
Dyadic International, Inc.
JUPITER, Fla., May 03, 2021 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI) a global biotechnology company focused on further improving, applying and...
Dyadic International, ‘변형 Dyadic C1 단백질 기술이 글로벌 보건 과제를 해결에 기여할 잠재력’ 주제로 파이어사이드 챗 개최
April 26, 2021 07:42 ET
|
Dyadic International, Inc.
미국 플로리다주 주피터, April 26, 2021 (GLOBE NEWSWIRE) -- 글로벌 바이오테크 기업인 Dyadic International, Inc. (NASDAQ: DYAI)은 2021년 5월 4일 오전 10시(미국동부시간) 파이어사이드 챗(fireside chat) 행사를 실시한다고 밝혔다. Dyadic International은 자체...
Dyadic International主办炉边谈话以讨论“变革型Dyadic C1蛋白质技术在帮助应对全球健康挑战方面的潜力”
April 26, 2021 07:42 ET
|
Dyadic International, Inc.
佛罗里达州朱庇特, April 26, 2021 (GLOBE NEWSWIRE) -- Dyadic International,...
Dyadic International veranstaltet Kamingespräch mit dem Titel „The Potential of the Transformative Dyadic C1 Protein Technology in Helping Meet Global Health Challenges“
April 26, 2021 07:42 ET
|
Dyadic International, Inc.
JUPITER, Fla., April 26, 2021 (GLOBE NEWSWIRE) -- Dyadic International, Inc. („Dyadic“, „wir“, „uns“, „unser“ oder das „Unternehmen“) (NASDAQ:DYAI), ein globales Biotechnologieunternehmen, das sich...
Dyadic International organise une discussion informelle sur « Le potentiel de la technologie transformatrice des protéines à cellules C1 de Dyadic pour aider à relever les défis mondiaux en matière de santé »
April 26, 2021 07:42 ET
|
Dyadic International, Inc.
JUPITER, Floride, 26 avr. 2021 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (« Dyadic », « nous », « notre », « nos » ou la « Société ») (NASDAQ : DYAI), une société mondiale de biotechnologie...